Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- TOPICS 2 articles
May 4, 2009
- Takeda Deals with Soaring R&D Costs through 2 Strategies
May 4, 2009
- Sanofi-aventis Aims at No. 5 Place in Japan in 5 Years: Dr Chocat
May 4, 2009
- Enhance Japan's Presence in Multinational Clinical Trials
May 4, 2009
- Market for Drugs for Hyperlipidemia to Exceed ¥400 Bil. in 2013: Fuji-Keizai Data Book
May 4, 2009
- NEDO to Start Large-Scale Clinical Trial on AD
May 4, 2009
- Shionogi to Develop In-house Products by Sugar Chain Analysis, Molecular Imaging
May 4, 2009
- Large-Scale Trial on Risk of Bone Fractures due to TZD Underway in Europe
May 4, 2009
- Gov't to Earmark ¥79.0 Bil. to Promote Development of Unapproved Drugs
May 4, 2009
- Santen Licenses Tapros to Merck
April 27, 2009
- Shire to Independently Commercialize "Ultra" Orphan Drugs in Japan
April 27, 2009
- Janssen Enters 2nd Growth Phase in 2009
April 27, 2009
- Combined Deficits for Health Insurance Societies Remain at Record-High Level
April 27, 2009
- MEDICAL DEVICE NEWS IN BRIEF
April 27, 2009
- No Progress on Discussions on Online Sales of OTC Drugs
April 27, 2009
- Taiyo Acquires Schering-Plough's Kasukabe Plant
April 27, 2009
- Korosho Proposes New Policy for Approval of Generics of Drugs Covered by Valid Use Patents
April 27, 2009
- R&D NEWS IN BRIEF
April 27, 2009
- CoreMed Expands Drug Development Support Services in Europe
April 27, 2009
- Potential Biomarker for Oxaliplatin Discovered: Prof. Tanigawara
April 27, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…